Cue Biopharma names Usman Azam as new CEO and president

30 September 2025

Boston, USA-based biotech Cue Biopharma (Nasdaq: CUE) has announced the appointment of Dr Usman Azam as its new president and chief executive (CEO), supporting the company’s advancement of its first-in-class tolerogenic drug candidate CUE-401 for autoimmune diseases, among other priorities.

Daniel Passeri will transition from his current role as CEO to one of strategic Aadvisor.

“This strategic transition in leadership is a timely and important step forward, enhancing the company’s next stage of corporate development with a prioritized focus on autoimmune disease,” said Daniel Passeri, chief executive of Cue Biopharma. “Dr Azam‘s significant experience across the entire drug development value-chain, including clinical trial design and execution, as well as product launches is invaluable for advancing the company’s first-in-class tolerogenic drug candidate CUE-401 for autoimmune diseases, our partnered program CUE-501 and for securing strategic partners for our clinical-stage CUE-100 series assets.”

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK